Zivin J A
Department of Neurosciences, University of California, San Diego, La Jolla 92093-0624, USA.
Neurology. 1999 Jul 13;53(1):14-9. doi: 10.1212/wnl.53.1.14.
Until 1995, treatment of strokes consisted exclusively of efforts to prevent recurrence. Proof that tissue plasminogen activator is useful for acute management is changing the approach to stroke patients. The development process has been difficult and the current treatment recommendations have been controversial. Recent successful clinical trials lend additional credence to these concepts. Future treatment strategies will probably include combinations of thrombolytics and neuroprotectants of various types. However, the need to initiate treatment rapidly after stroke onset is likely to continue.
直到1995年，中风的治疗仅仅局限于预防复发的措施。组织纤溶酶原激活剂对急性中风治疗有效的证据正在改变对中风患者的治疗方法。其研发过程艰难，目前的治疗建议也存在争议。近期成功的临床试验为这些理念增添了更多可信度。未来的治疗策略可能会包括各种类型的溶栓剂和神经保护剂的联合使用。然而，在中风发作后迅速开始治疗的必要性可能会持续存在。
